Viatris (VTRS) Share-based Compensation (2020 - 2026)
Viatris' (VTRS) quarterly Share-based Compensation came in at $56.5 million in Q1 2026, up 92.83% year-on-year from $29.3 million in Q1 2025, and up 157.59% quarter-over-quarter from -$98.1 million in Q4 2025.
Viatris (VTRS) Share-based Compensation (2020 - 2026) Analysis & Trends
Viatris' Share-based Compensation history runs 7 years deep, the most recent figure standing at $56.5 million for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 92.83% year-over-year to $56.5 million in Q1 2026; TTM through Mar 2026 was $57.4 million, a 60.87% decrease from a year earlier, with the FY2025 full-year figure at $30.2 million, down 79.33% from the prior year.
- Share-based Compensation climbed to $56.5 million in Q1 2026 per VTRS's latest filing, from -$98.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $94.9 million in Q3 2023 and bottomed at -$98.1 million in Q4 2025.
- The 5-year median for Share-based Compensation is $29.5 million (2022), against an average of $24.2 million.
- Across the five-year window, Share-based Compensation surged 708.33% in 2022 and tumbled 392.91% in 2023, its largest moves.
- Year by year, Share-based Compensation stood at $29.6 million in 2022, then tumbled by 392.91% to -$86.7 million in 2023, then jumped by 207.04% to $92.8 million in 2024, then plunged by 205.71% to -$98.1 million in 2025, then jumped by 157.59% to $56.5 million in 2026.
- Per Business Quant, the three latest VTRS Share-based Compensation figures stand at $56.5 million (Q1 2026), -$98.1 million (Q4 2025), and $36.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.50 Mn |
| Mar 31, 2026 | 56.50 Mn |
| Dec 31, 2025 | -98.10 Mn |
| Dec 31, 2025 | -98.10 Mn |
| Sep 30, 2025 | 36.00 Mn |
| Sep 30, 2025 | 36.00 Mn |
| Jun 30, 2025 | 63.00 Mn |
| Jun 30, 2025 | 63.00 Mn |
| Mar 31, 2025 | 29.30 Mn |
| Mar 31, 2025 | 29.30 Mn |
| Dec 31, 2024 | 92.80 Mn |
| Dec 31, 2024 | 92.80 Mn |
| Sep 30, 2024 | -28.10 Mn |
| Sep 30, 2024 | -28.10 Mn |
| Jun 30, 2024 | 52.70 Mn |
| Jun 30, 2024 | 52.70 Mn |
| Mar 31, 2024 | 28.70 Mn |
| Mar 31, 2024 | 28.70 Mn |
| Dec 31, 2023 | -86.70 Mn |
| Dec 31, 2023 | -86.70 Mn |